Dysautonomia Clinic

10/21/2025

🎉 Dysautonomia Clinic Research Team is excited to share our new study on autonomic dysfunction and comorbidities in h- and hypermobility spectrum disorders (HSD)! The study found significant autonomic dysfunction in women with h-EDS/HSD, which was more severe than in patients with multiple sclerosis, diabetic neuropathy, scleroderma, and psoriatic arthritis. Quality of life was also worse than in patients with POTS, multiple sclerosis, rheumatoid arthritis, and lupus. 25% of patients had a clinical triad of EDS, POTS and MCAS. ‼️

Read full-length article here. 👇
https://www.sciencedirect.com/science/article/pii/S1566070225001183?dgcid=author

10/06/2025

We are excited to announce that Nicole Freyschlag, MS, has joined Dysautonomia Clinic as a nutrition consultant! With the Master’s Degree in Human Nutrition and Functional Medicine, Nicole takes a science-based, patient-centered approach to health, focusing on personalized nutrition and lifestyle strategies to reduce symptoms and improve well-being. If you would like to have a nutrition consult, please e-mail to admin@amherstneurology.com.
http://www.dysautonomiaclinic.com/meet-the-team/

09/29/2025

‼️ Finally, after being the most downloaded and viewed paper on Preprints.org in neurology and neuroscience, we are excited to announce that our paper on immunotherapies in POTS, other common autonomic disorders and Long COVID has been published in its final form! Congratulations to Jacobs School of Medicine & Biomedical Sciences - University at Buffalo medical students, who are a part of our Dysautonomia Clinic Research Team: Gabriela Funez-dePagnier, Anna Szombathy and Meagan Hutchinson - all future neurologists! Their hard work and dedication on this comprehensive review will undoubtedly pave the way for future therapeutics in autonomic disorders! 🧠🩺

Read full-length article here: 👇

Postural orthostatic tachycardia syndrome (POTS), neurocardiogenic syncope, and orthostatic hypotension are the most common autonomic disorders encountered i...

09/26/2025

It's possible that even generic drugs will be or are already affected by Pharma changing their processing or using cheaper ingredients in an attempt to cut cost. If you've recently experienced new side effects from medications of the same brand that you've been taking for years, let us know in the comments!

President Donald Trump announced Thursday that brand-name or patented pharmaceutical products will be subject to a 100% tariff starting October 1 – unless the drugmaker is building a manufacturing plant in the US.

09/24/2025

Question for patients who take atenolol by Teva USA or another brand: have you noticed new-onset body tingling after taking atenolol whereas that didn't happen in the past when you took this medication? A few of our patients developed new-onset body tingling (paresthesia) within a few hours of taking atenolol, a side effect that they never experienced before on this brand so we're trying to determine if Teva changed their atenolol formulation recently. Thanks!

09/21/2025

Thanks to the The Ehlers-Danlos Society for inviting Dr. Blitshteyn to lead the CME course on neurologic and neurosurgical manifestations of /HSD at the 2025 International Scientific Symposium in Toronto, Canada. Many diverse topics were discussed, including , , , , Chiari malformation, cranio-cervical instability and others.

08/27/2025

🫶

08/05/2025

🙏 Thanks to Newsweek for their report on POTS and interviewing Dr. Blitshteyn and other top specialists. Dr. Svetlana Blitshteyn said, "POTS can often be misdiagnosed with anxiety, depression, panic disorder, anemia, dehydration and many others, so when a doctor doesn't know much about POTS, they are most likely to misdiagnose it."

Dr. Blair Grubb added: "It's very unfortunate because these people are mistreated and ignored, and I think the real reason is many of them are women. If this was a disease principally in men, it would be taken more seriously." 🎯💯

PoTS results in a wide range of symptoms, particularly when standing, such as increased heart rate, chest pain and feeling faint.

08/03/2025

Thanks to Springer Nature, you can now read Dr. Blitshteyn's and Aliya Hyman's new paper on Harlequin syndrome free of charge!

08/02/2025

🎉 Congratulations to our amazing Jacobs School of Medicine & Biomedical Sciences - University at Buffalo medical student, Aliya Hyman, who is a part of our Dysautonomia Clinic Research Team, on publishing her first paper, which is on Harlequin syndrome - a rare autonomic disorder. 🎉

Unfortunately, there is no free open access to read this full-length paper unless your institution has a subscription to this journal.

https://link.springer.com/article/10.1007/s10072-025-08387-1

07/28/2025

💥 We are incredibly excited to have Dr. Bonnie Floyd, PhD, a clinical psychologist, join our Dysautonomia Clinic Team! Dr. Floyd received her PhD in Clinical Health Psychology from Albert Einstein College of Medicine because it combined her dual interests in clinical psychology and medicine.

Dr. Floyd is uniquely trained in assisting patients who have been diagnosed with chronic illness to have the best possible quality of life. As a patient herself with multiple sclerosis, Dr. Floyd has written a book, “Remarkable Journey: My Dual Diagnoses as Doctor and Patient,” which describes her professional and personal experiences of living with a chronic medical condition.

Dr. Floyd is scheduling patients of Dysautonomia Clinic for September 2025. If you'd like to schedule an appointment with Dr. Floyd, please e-mail to admin@amherstneurology.com. 🧠

http://www.dysautonomiaclinic.com/meet-the-team/

07/22/2025

‼️ Read this paper describing a large case series of patients with mast cell activation syndrome (MCAS) and comorbidities, whose MCAS-associated symptoms improved significantly on GLP1 agonists.

📌 To summarize:
✔️ 47 patients (mean age 39, range 15–71, 89% female) included - all from the co-authors who are experts in MCAS and comorbidities, including from our Dysautonomia Clinic!
✔️ 89% of patients demonstrated clinical benefit with GLP-1RAs for a broad range of problems associated with MCAS.
✔️ Obviously, GLP-1RAs were used for overweight, obesity, type 2 DM and off label by patients who could afford them.
✔️ No major adverse events occurred, GLP-1RAs were well-tolerated in this case series
✔️ Randomized controlled trials are needed to determine whether GLP-1RAs are effective - and at what dose - in patients with MCAS.

https://www.sciencedirect.com/science/article/pii/S0002962925011061?dgcid=coauthor